Michael McElhaugh
Chief Executive Officer at ARBUTUS BIOPHARMA CORPORATION
Net worth: 4 M $ as of 2024-04-29
Michael McElhaugh active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Director/Board Member | 2023-12-31 | - |
| Chief Executive Officer | 2023-12-31 | - | |
| Chief Operating Officer | 2022-10-31 | - | |
| President | 2023-12-31 | - | |
| Corporate Officer/Principal | 2018-11-30 | 2022-10-31 | |
Arbutus Biopharma, Inc.
 Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Chief Executive Officer | 2023-12-31 | - |
| President | 2023-12-31 | - |
Career history of Michael McElhaugh
Former positions of Michael McElhaugh
| Companies | Position | Start | End |
|---|---|---|---|
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Corporate Officer/Principal | 2008-08-31 | 2012-02-29 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Chief Operating Officer | 2012-04-30 | - |
| Founder | 2012-04-30 | - |
Training of Michael McElhaugh
| St. Joseph's University | Undergraduate Degree |
| Thomas Jefferson University | Graduate Degree |
| Johnson Graduate School of Management | Masters Business Admin |
Statistics
International
| United States | 8 |
Operational
| Corporate Officer/Principal | 3 |
| Chief Operating Officer | 2 |
| Chief Executive Officer | 2 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private companies | 2 |
|---|---|
Arbutus Biopharma, Inc.
Arbutus Biopharma, Inc. BiotechnologyHealth Technology Arbutus Biopharma, Inc. engages in the research and development of pharmaceutical products for Hepatitis B. Its operation includes covalently closed circular DNA, Capsid Assembly, Cyclophilins, and Surface Antigen. The company was founded by Patrick T. Higgins, Michael J. Sofia, Michael J. McElhaugh, and Bryce A. Roberts in May 2012 and is headquartered in Doylestown, PA. | Health Technology |
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
- Stock Market
- Insiders
- Michael McElhaugh
- Experience
